Clinical efficacy of recombinant canine interferon‐gamma therapy in dogs with cutaneous epitheliotropic T‐cell lymphoma

Abstract

AbstractBackgroundThe antitumour effects of interferon‐gamma (IFN‐γ) in humans with cutaneous epitheliotropic T‐cell lymphoma (CETCL) have been described; however, the efficacy of IFN‐γ in dogs has not been investigated.Hypothesis/ObjectivesThe aim of this study was to evaluate the efficacy of recombinant canine IFN‐γ (rCaIFN‐γ) therapy in dogs with CETCL.AnimalsTwenty dogs with CETCL recruited from seven veterinary clinics were enrolled in the study.Materials and MethodsFifteen dogs were treated with rCaIFN‐γ, and five control dogs were treated with prednisolone. We evaluated survival time, skin lesions (erythema, nodules, ulcers and bleeding), pruritus and general condition (sleep, appetite and body weight). In the rCaIFN‐γ group, a questionnaire regarding the therapy was administered to owners after the dogs died.ResultsNo significant differences existed in the median survival time between the rCaIFN‐γ and control groups (log‐rank test:p = 0.2761, Wilcoxon's rank sum test: p = 0.4444). However, there were significant differences in ulcer, bleeding, pruritus, sleep, appetite and body weight between the groups (Wilcoxon–Mann–Whitney U‐test:p = 0.0023,p = 0.0058,p = 0.0005,p = 0.0191,p = 0.0306 andp = 0.0306, respectively). Two (40%) of five dogs were euthanised in the control group, compared with none in the rCaIFN‐γ group. Fourteen questionnaires were collected, and owners reported that they were satisfied with the rCaIFN‐γ treatment.Conclusions and Clinical RelevanceAlthough the median survival time was not prolonged, rCaIFN‐γ could be helpful in maintaining good quality of life for dogs with CETCL.